Moghimi Seyed Moein, Farhangrazi Zahra Shadi
Nanomedicine Research Group, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
Nanomedicine. 2014 Nov;10(8):1661-6. doi: 10.1016/j.nano.2014.04.011.
Contrary to high expectations, the majority of clinically approved anti-cancer nanomedicine, and those under clinical trials, have shown limited therapeutic efficacy in humans. So, why these nanomedicine are not delivering their promise? Here, we discuss likely factors, and call for a paradigm shift in approach and design of future cancer nanotherapeutics based on realistic cancer models representing human disease, and better understanding of integrated pathophysiological processes, including systems immunology, that modulate human tumor functionality and growth.
This critical review of the current state of translational oncology research utilizing nanomedicine-based approaches provides a comprehensive discussion of the multiple factors that are responsible for poor outcomes when translating these approaches models to the actual human disease.
与人们的高度期望相反，大多数临床批准的抗癌纳米药物以及那些正在进行临床试验的药物，在人体中显示出有限的治疗效果。那么，为什么这些纳米药物没有兑现它们的承诺呢？在此，我们讨论可能的因素，并呼吁基于代表人类疾病的现实癌症模型以及对包括系统免疫学在内的调节人类肿瘤功能和生长的综合病理生理过程的更好理解，在未来癌症纳米治疗的方法和设计上进行范式转变。
这篇对利用基于纳米药物的方法进行转化肿瘤学研究现状的批判性综述，全面讨论了将这些方法模型转化为实际人类疾病时导致不良结果的多种因素。
